A groundbreaking brain implant developed by Synchron has enabled an ALS patient to control Amazon’s Alexa digital assistant using only his thoughts. This technology opens doors for individuals with disabilities to regain independence and interact with smart home devices in a hands-free and voice-free manner.
NeuroSense Therapeutics is in advanced discussions with major pharmaceutical companies for a potential partnership to develop and commercialize its ALS drug candidate, PrimeC. The company anticipates receiving terms for the partnership in the fourth quarter of 2024, based on promising Phase 2b trial data showing PrimeC’s efficacy in mitigating ALS progression and improving survival rates.
A groundbreaking brain-computer interface (BCI) has allowed a man with ALS to regain a form of speech. The BCI, developed by scientists at the University of California, translates brain signals into words, giving the patient a new way to communicate.
Scientists have identified a gene mutation linked to the rare recovery of ALS patients, offering a potential new avenue for treatment. The mutation in the IGFBP7 gene enhances the activity of IGF-1, a protein that protects motor neurons. While more research is needed, this finding could lead to new therapies for ALS.
Former NFL player Steve Gleason, diagnosed with ALS in 2011, has found a new way to express his creativity through AI-generated art. His series ‘Resilient Spirit’ showcases vibrant, symbolic images that explore themes of hope, resilience, and the power of the human spirit.
